Variant
SMARCA4 INACTIVATING MUTATION
CI-VAR-00002034Explore in graph →CIViC 218
Curated evidence
Evidence by cancer (3 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24658004
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Lung Adenocarcinoma1 | ||||||||
| SMARCA4 INACTIVATING MUTATION | (prognostic) | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID513In patients with lung adenocarcinoma, those with loss-of-function mutations in SMARCA4 had worse overall survival than those with only missense or no mutations. PMID 24658004 · Jelinic et al., 2014 · Open in CIViC | civic |
| Lung Non-Small Cell Carcinoma1 | ||||||||
| SMARCA4 INACTIVATING MUTATION | Tozasertib | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID5928AURKA activity is essential in NSCLC cells lacking SMARCA4/BRG1. In these cells, RNAi-mediated depletion or chemical inhibition of AURKA induces apoptosis and cell death in vitro and in xenograft mous… (full text at CIViC) PMID 28102363 · Tagal et al., 2017 · | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available